Trial Profile
A multicenter, randomized, double-blind, placebo-controlled, parallel-design, exploratory study of orally administered ERB-041 [prinaberel] in subjects with active interstitial cystitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2020
Price :
$35
*
At a glance
- Drugs Prinaberel (Primary)
- Indications Interstitial cystitis
- Focus Therapeutic Use
- 28 Sep 2020 Status changed from discontinued to withdrawn prior to enrolment.
- 29 Mar 2007 New trial record.